Inflammation of the Ileal Conduit from Immune Checkpoint Inhibitor Use
Author Information
Author(s): K Kobayashi, Kohei Hashimoto, Toshiaki Tanaka, Naoya Masumori
Primary Institution: Sapporo Medical University School of Medicine
Hypothesis
Can pembrolizumab cause inflammation of the ileal conduit in patients with metastatic bladder cancer?
Conclusion
Inflammation of an ileal conduit can occur as an immune-related adverse event caused by metastatic urothelial carcinoma treatment with pembrolizumab.
Supporting Evidence
- The patient experienced abdominal distention and was diagnosed with enterocolitis after receiving pembrolizumab.
- Biopsy results confirmed inflammation in the ileal conduit.
- Treatment with prednisolone led to improvement in symptoms and mucosal healing.
Takeaway
A patient treated for bladder cancer with a drug called pembrolizumab developed inflammation in a part of his intestine used for urine diversion, but he got better after treatment with steroids.
Methodology
The case involved a patient who received pembrolizumab and was diagnosed with enterocolitis after presenting with abdominal symptoms, confirmed by imaging and biopsy.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 69-year-old man with metastatic bladder cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website